Corrected Left Ventricular Electrical Delay Predicting Response to Cardiac Resynchronization Therapy
A Prospective Clinical Trial of Corrected Left Ventricular Electrical Delay Predicting Response to Cardiac Resynchronization Therapy in Chinese With Heart Failure
1 other identifier
observational
60
1 country
1
Brief Summary
Cardiac resynchronization therapy (CRT) is a well-established treatment for patients with severe systolic heart failure (HF) and ventricular desynchronization. Despite the consistently observed structural and functional improvements as well as reductions in HF events and mortality in large multicenter randomized trials, 30% patients remain classified as nonresponders. Present evidences showed that QRS duration was the most effective parameter to predict responsivity of CRT in patients with severe HF. But some studies showed that QRS duration could be influenced by obesity and gender. Accordingly, the simple QRS interval width of body surface electrocardiograph should not be the most satisfactory parameter for screening patients suitable for CRT. Recent study showed that left ventricular electrical delay, as measured by the time from the onset of QRS to the LV electrogram peak (QLV), predicted CRT response. At long QLV intervals, atrioventricular optimization (AVO) can increase the likelihood of structural response to CRT. However, it is unclear whether it is suitable for Chinese patients. The investigators would like to validate this relation in a Chinese population and explore if a corrected QLV might do better to predict the responsivity of CRT.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Dec 2014
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2014
CompletedFirst Submitted
Initial submission to the registry
July 2, 2015
CompletedFirst Posted
Study publicly available on registry
July 10, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2018
CompletedApril 28, 2017
April 1, 2017
3.5 years
July 2, 2015
April 27, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Left Ventricular End Systolic Volume (LVESV)
change in LVESV
baseline and 6 months
Secondary Outcomes (2)
New York Heart Association (NYHA)
baseline and 6 months
left ventricular ejection fraction (LVEF)
baseline and 6 months
Study Arms (1)
heart failure
heart failure patients with CRT
Eligibility Criteria
Heart failure patients received CRT in Sun Yat-sen Memorial Hospital, Sun Yat-sen University. Informed consent must be obtained for all of the included patients.
You may qualify if:
- More than 18 Years
- Informed consent signed
- NYHA class ≥ II, an ejection fraction of ≤ 0.35, QRS duration of ≥ 150 milliseconds with Non-LBBB) or ≥ 120 milliseconds with LBBB, who treated with CRT
- The Estimated survival time was more than one year
- sinus rhythm, pacemaker independent
You may not qualify if:
- NYHA class I symptoms
- Severe liver or kidney dysfunction
- Valvular heart disease
- Pregnancy or lactation women
- percutaneous coronary intervention (PCI) or cardiac artery bypass graft (CABG) within 3 month
- Have malignant tumors and the Estimated survival time was less than one year
- an enzyme-positive myocardial infarction within 3 months before enrollment, or atrial fibrillation
- any reasons cannot complete follow-up; Or researchers think that don't suit to be included in the research of other conditions
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Universitylead
- Southern Medical University, Chinacollaborator
- Fudan Universitycollaborator
- Beijing Chao Yang Hospitalcollaborator
- The First Affiliated Hospital with Nanjing Medical Universitycollaborator
- First Affiliated Hospital, Sun Yat-Sen Universitycollaborator
Study Sites (1)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, 510120, China
Study Officials
- PRINCIPAL INVESTIGATOR
Jingfeng Wang, M.D., Ph.D.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- subdecanal
Study Record Dates
First Submitted
July 2, 2015
First Posted
July 10, 2015
Study Start
December 1, 2014
Primary Completion
June 1, 2018
Study Completion
December 1, 2018
Last Updated
April 28, 2017
Record last verified: 2017-04